(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credit: AP
The Ebola outbreak in the Democratic Republic of Congo (DRC) is worsening, with confirmed cases rising to 1,048 and the death toll reaching 267, according to government data.
The country has also reported 112 recoveries, while contact tracing coverage has improved to 70.8%. However, significant gaps remain. The World Health Organization (WHO) estimates that at least 95% of contacts must be traced to effectively contain an outbreak.
The outbreak caused by the Bundibugyo strain, with no vaccine or anti-viral, is spreading rapidly, even as response measures are being intensified.
"The outbreak remains serious and is evolving very fast. However, I have seen a response that is growing stronger every day," said Marie-Roseline Belizaire, WHO Regional Emergencies Director for Africa, speaking to reporters in Bunia, the epicenter of the outbreak.
Meanwhile, Israel's Health Ministry said test results for two men hospitalized on suspicion of Ebola infection were negative.
The ministry stressed that no confirmed Ebola case has been diagnosed in Israel and advised the public to avoid non-essential travel to areas experiencing active outbreaks.
In addition, it urged travelers returning from Ebola-affected regions who develop fever or unusual symptoms within 21 days of their return to stay home and avoid contact with others.
UNICEF has warned that nearly 3 million children and adolescents face growing risks in eastern DRC.
According to the UN agency, an estimated 2.95 million children and adolescents aged 18 and under — representing 54% of the population across 31 affected health zones — are at risk from both Ebola and the disruption of essential services.
In Ituri province alone, Ebola has left more than 130 children orphaned, creating an urgent need for protection and care.
“Our teams in Ituri have met children who have lost their mothers, and in some cases both parents, to Ebola," said UNICEF Executive Director Catherine Russell. "Children are trying to make sense of the threat while surrounded by rumors and online misinformation.”
Although the situation remains fluid, children and adolescents account for approximately 15% of confirmed Ebola cases and more than 25% of confirmed deaths in eastern DRC as of June 19.
Children and adolescents with confirmed Ebola are almost twice as likely to die as adults, highlighting the disproportionate impact of the outbreak on younger populations.
In Uganda, 20 Ebola cases and two deaths have been confirmed among individuals who travelled from the DRC seeking testing and treatment.
Children have also been affected. One child has tested positive for Ebola, while 19 others are under quarantine monitoring, the UNICEF said.
“Children are especially vulnerable because they depend on caregivers and cannot distance themselves from a sick parent or sibling in the same way that an adult can. To better protect children, we need sustained access, and the resources needed to reach every affected community," Russell added.
Credit: Instagram
Marketa Vondrousova, the 2023 Wimbledon singles champion, has been banned from professional sport for four years after refusing an anti-doping test.
According to an independent tribunal, the 26-year-old provided “no compelling justification” for declining to provide a sample after being notified at her home by a doping control officer in December.
“We recognize that this is a significant ban. And the reason for that is that you can’t have an anti-doping system where a player is in a better place by refusing to take a test than they would be by taking the test and testing positive,” said Karen Moorhouse, chief executive of the International Tennis Integrity Agency (ITIA).
“That feeds into the structure of the doping rules that provides for a starting point of a four-year ban for refusing to take a test, the same as a starting point for testing positive,” she added.
The Czech player said in April that she feared for her safety when the officer called and claimed the officer had failed to follow protocol.
Vondrousova reached the French Open final in 2019, won an Olympic silver medal in 2021, and achieved a career-high ranking of No. 6.
“I have never doped, I have never had a positive test. Throughout my entire career, I have undergone countless anti-doping controls and have always stepped onto the court with a clear conscience. I cannot say what comes next. For the first time in my life, I do not have a plan,” she said in a statement.
She is suspended from all professional events until June 21, 2030, but has the right to appeal the decision to the Court of Arbitration for Sport (CAS).
According to Vondrousova, the doping control officer did not adhere to the rules by approaching her outside the hour she had designated under the whereabouts rules. During the hearing, Vondrousova said stress and poor mental health had affected her decision-making, in addition to her safety concerns.
Also read: Why Sleeping Pill Addiction Is Common Among Football Players
Doping control (testing) is one tool that Anti-Doping Organizations (ADOs) use to level the playing field and protect clean sport.
As per the World Anti-Doping Agency (WADA), athletes playing at the national or international level can be subject to doping control and can be tested anytime or anywhere.
Credit: iStock
Amid a red alert for a severe heatwave in the UK, the Met Office has also warned of a "pollen bomb" that could significantly affect people with hay fever.
The forecaster said there is no evidence that pollen levels are worse this year, but symptoms may feel more severe due to a combination of high pollen counts and exposure to multiple pollen types.
A 2026 Lancet Countdown in Europe study found that climate change is altering the flowering seasons of plants that release allergenic pollen.
“The combination of the fairly breezy and dry weather is going to bring a lot of pollen into the air this week and for the coming weeks,” Alastair Culham, Professor of Botany at the University of Reading, told The Independent.
“We've seen quite a mixed year so far, a very warm, dry spring which brought pollen on early, and then a series of wet weather which has allowed the grasses to grow exceptionally well. Now the weather has warmed and dried, those grasses are going into flower and the level of pollen from grass is phenomenally high,” he added.
Also read: UK Issues Red Heat-Health Alert: How to Protect Yourself From Extreme Heat
Rising temperatures, expected to exceed 30°C on several days this week, are causing trees and grasses to release large amounts of pollen into the air.
“Hay fever symptoms usually appear when the pollen count, which is a measure of the number of grains of pollen in one cubic meter of air, exceeds 50,” the Met Office said.
The agency noted that weather conditions influence how much pollen is released and spread. Humid and windy conditions help pollen travel, while rain can clear it from the air. On sunny days, pollen levels are typically highest in the early evening.
Read To Know: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
The Met Office has warned that grass pollen will remain at high levels across England and Wales, with Yorkshire, the Midlands and the North West expected to experience very high counts.

Pollen levels are forecast to be very high across England on June 24, with temperatures reaching around 38°C in some areas.
Northern Ireland and Scotland are also expected to experience medium to high pollen levels throughout the week.
Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries
Hay fever is a common allergy that causes sneezing, coughing and itchy eyes.
According to Allergy UK, one in four adults and one in eight children suffer from allergic rhinitis, the medical term for hay fever. Research suggests the number of sufferers is increasing each year.
The Lancet study found that hay fever sufferers now experience symptoms for up to two weeks longer than they did in the 1990s due to climate change.
According to the UK NHS, hay fever can last for weeks or months, unlike a cold, which usually resolves within one to two weeks. While there is no cure, symptoms can be managed when pollen levels are high.
© 2024 Bennett, Coleman & Company Limited